Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prost... (iopharm Group Debiopharm Group is a g...)

HOME >> MEDICINE >> NEWS

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

Date:11/13/2008

iopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

Debiopharm S.A. Contacts Additional Media Contacts

In London

Maurice Wagner Maitland

Director Corporate Affairs & Brian Hudspith

Communications Tel: +44 (0)20 7379 5151

Tel.: +41 (0)21 321 01 11 bhudspith@maitland.co.uk

Fax : +41 (0)21 321 01 69

mwagner@debiopharm.com

Jo-Anne Lutjens In New York

Communications Manager Russo Partners, LLC

Tel.: +41 (0)79 370 27 15 Wendy Lau